ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 854

Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort

Elena Nikiphorou1, Sofia Ramiro 2, Alexandre Sepriano 3, Adeline Ruyssen Witrand 4, Robert B.M. Landewé 5 and Désirée van der Heijde 3, 1King's College London, London, United Kingdom, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology center, Pierre Paul Riquet Hospital, CHU of Toulouse, Paul Sabatier University, UMR 1027, Inserm, France, Toulouse, France, 5Amsterdam University Medical Center, Amsterdam, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, Imaging, Inflammation, socioeconomic factors and job

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE) factors (e.g. physically demanding jobs) may modify these associations.The study investigates the relationship between smoking and imaging outcomes (SI joints, spine, MRI and radiographs) over time in axSpA, to assess if SE factors first modify and if not, confound, such a relationship.

Methods: Patients with axSpA from the DESIR cohort who fulfil the ASAS axSpA classification criteria were included. Four imaging continuous outcomes (X-ray spine [mSASSS, range 0-72]; X-ray SIJs modified New York grading [mNY, 0-8]; MRI-Spine [SPARCC, range 0-414] and MRI-SIJ [SPARCC, range 0-72]) have been scored by 3 central readers independently (average score used) in one session, blinded for time order (baseline, 2 and 5 years). Smoking was tested as a binary variable: smoking status since last visit. SE variables were: age, gender, ethnicity (Caucasian vs other), job type based on ‘collar’ (blue [manual labour work] vs white [office-based work]); educational status (low vs high [university]); marital status (married vs not) and parental (number of children) status. Potential interactions between smoking and SE factors were first investigated and, if statistically (p< 0.15) and clinically relevant, models were stratified. The effect of smoking on imaging outcomes was assessed in multivariable time-varying models using generalized estimating equations adjusted for other possible confounders.

Results: In total, 425 axSpA patients were included: 225 [53%] male, 167 [40%] smokers and 287 [68%] blue collar. The mean baseline (SD) MRI-SIJ SPARCC was 4.67 (7.85), MRI-spine SPARCC: 2.73 (7.95)); mSASSS: 0.39(1.66); mNY: 1.70(1.84)). A significant interaction was found between smoking and job type with MRI-SIJ inflammation as the outcome (p=0.031) as well as with mNY grading (p=0.096). Similarly, educational status also proved to modify the association between smoking and MRI-SIJ inflammation (p=0.026). In the multivariable models, smoking was significantly associated with more MRI-SIJ inflammation over 5 years of follow-up but only in patients with a blue-collar job (β [95% CI]: 3.35 [0.54,6.17]) (table). Results were similar in the low education stratum (β [95% CI]: 2.69 [0.48, 4.91]. Smoking was not significantly associated with any of the other imaging outcomes over time. Male gender was positively associated with MRI-SIJ inflammation regardless of job type, and also with MRI-Spine inflammation and structural damage although only for blue-collar patients in the case of SIJ damage.

Conclusion: There is a strong association between smoking and MRI-SIJ inflammation over time in axSpA patients with blue collar job type or low education, irrespective of other socio-economic factors, systemic inflammation and treatment. These findings suggest a possible role for mechanical stress (seen with manual jobs) amplifying the effect of smoking on axial inflammation in axSpA. No significant relationship was found between smoking and spinal inflammation or axial damage, possibly also due to the limited imaging changes in this cohort.


Disclosure: E. Nikiphorou, AbbVie, 8, Celltrion, 5, 6, Eli Lilly, 8, Eli Lilly and Company, 8, Gilead, 5, 6, Pfizer, 8, Sanofi, 5, 8; S. Ramiro, AbbVie, 5, 8, Eli Lilly, 5, 8, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sanofi, 5, 8; A. Sepriano, None; A. Ruyssen Witrand, None; R. Landewé, Abbott, 2, 5, 8, Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 8, Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 2, AbbVie, 5, Abbvie, 5, 8, AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GSK, Novartis, Merck, Pfizer, Roche, Schering- Plough, UCB, Wyeth, 5, Ablynx, 5, Amgen, 2, 5, 8, AstraZeneca, 5, BMS, 5, 8, Bristol Myers Squibb, 5, 8, Bristol-Myers Squibb, 5, Celgene, 5, 8, Centocor, 2, 5, 8, Director of Rheumatology Consultancy BV, which is a registered company under Dutch law, 6, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Eli-Lilly, 5, 8, Galapagos, 5, 8, Gilead, 5, 8, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, 8, Janssen, 5, 8, Merck, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Rheumatology bv, 4, Rheumatology Consultancy BV, 9, Roche, 2, 5, 8, Schering-Plough, 2, 5, 8, UCB, 5, 8, UCB Pharma, 2, 5, 8, Wyeth, 2, 5, 8; D. van der Heijde, AbbVie, 5, AbbVie, Amgen, Astellas, AstraZeneca, BMS, 5, Amgen, 5, Astellas, 5, 9, Astellas Pharma, 5, AstraZeneca, 5, BMS, 5, Boehringer Ingelheim, 5, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb, 5, Celgene, 5, Daiichi, 5, 9, Daiichi Sankyo, 5, Director of Imaging Rheumatology, 6, Director of Imaging Rheumatology bv, 9, Eli Lilly, 5, Eli Lilly and Company, 5, Eli-Lilly, 5, Galapagos, 5, Gilead, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, GSK, 5, 8, Imaging Rheumatology bv, 9, Imaging Rheumatology BV, 9, Imaging Rheumatology bv., 9, Janssen, 5, 8, Janssen Pharmaceutica, 5, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, Regeneron, 5, 8, Rheumatology bv, 4, 9, Roche, 5, 8, Sanofi, 5, 8, Takeda, 5, 8, Takeda Pharmaceutical Company, 5, UCB, 5, 8, UCB Pharma, 5.

To cite this abstract in AMA style:

Nikiphorou E, Ramiro S, Sepriano A, Ruyssen Witrand A, Landewé R, van der Heijde D. Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/do-smoking-and-socio-economic-factors-independently-influence-imaging-outcomes-in-axial-spondyloarthritis-five-year-data-from-the-desir-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-smoking-and-socio-economic-factors-independently-influence-imaging-outcomes-in-axial-spondyloarthritis-five-year-data-from-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology